foxo4 dri senolytic peptide human trial 2024 2025 PDF) The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI general inflammation SS-31 Reconstitution: 5mg + Strength:2000mcg
SKU: 90121362433
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19